Hemisphere GNSS Introduces GradeMetrix® Loader Kit
26 oct. 2022 23h00 HE
|
Hemisphere GNSS (989444)
MUNICH, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Hemisphere GNSS, Inc. announces the release of the GradeMetrix® Loader solution. Recognizing the growing global demand and versatility of the loader,...
Hemisphere GNSS Introduces GradeMetrix® Scraper
25 oct. 2022 09h00 HE
|
Hemisphere GNSS (989444)
MUNICH, Oct. 25, 2022 (GLOBE NEWSWIRE) -- Hemisphere GNSS, Inc. announces the release of the GradeMetrix® Scraper Solution for pull pan and belly pan scrapers. "We believe by introducing...
Revolution Medicines Strengthens Senior Management Team with Promotions and a New Hire
01 sept. 2022 16h05 HE
|
Revolution Medicines, Inc.
Company Promotes Jack Anders to Chief Financial Officer and Jeff Cislini to General Counsel Daniel Simon to Join Company as Chief Business Officer REDWOOD CITY, Calif., Sept. 01, 2022 (GLOBE...
Revolution Medicines Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
22 juil. 2022 16h02 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 22, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Pricing of Upsized $230.0 Million Public Offering of Common Stock
19 juil. 2022 22h41 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Announces Commencement of Public Offering of Common Stock
19 juil. 2022 16h01 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., July 19, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...
Revolution Medicines Advances First RAS(ON) Inhibitor into Clinic, Dosing First Patient in Phase 1/1b Trial of RMC-6236
28 juin 2022 07h00 HE
|
Revolution Medicines, Inc.
First-in-class, oral, RAS(ON) Inhibitor being evaluated initially in patients with cancers driven by KRASG12 mutations Sushil Patel, Ph.D., industry veteran with commercial oncology expertise,...
EarthScout Launches New Mini Wireless Soil Cub Field Sensor
12 avr. 2022 08h30 HE
|
EarthScout
MINNEAPOLIS, April 12, 2022 (GLOBE NEWSWIRE) -- Agtech company EarthScout today announced a new addition to its scalable line of agriculture smart products that help farmers and food producers...
Piezo Motion’s Precise Motor Technology Is Now Available in Germany
24 mars 2022 08h00 HE
|
Brain Scientific Inc.
LAKEWOOD RANCH, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- Piezo Motion, a Brain Scientific (OTCQB:BRSF) company, and MEV Elektronik Service GmbH, a manufacturing representative...
Revolution Medicines Announces Seven Oral Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2022
09 mars 2022 07h30 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., March 09, 2022 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today...